Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -18.18% is 67% above its 5-year average of -54.94%, near the high end of its 5-year range (-187.74%–0.19%).
81.71% below its 12-month average of -10.00%.
Reported quarterly return on assets; no daily interpolation. Q1 FY2027 (2026-06-30): -0.65%.
RETURN ON ASSETS (ROA)
-18.18%
RETURN ON ASSETS (ROA) AVG TTM
-10.00%
RETURN ON ASSETS (ROA) AVG 3Y
-29.10%
RETURN ON ASSETS (ROA) AVG 5Y
-54.94%
RETURN ON ASSETS (ROA) AVG 10Y
-43.53%
RETURN ON ASSETS (ROA) AVG 15Y
-32.50%
RETURN ON ASSETS (ROA) AVG 20Y
-18.16%
CURRENT VS TTM AVG
-81.71%
CURRENT VS 3Y AVG
+37.53%
CURRENT VS 5Y AVG
+66.91%
CURRENT VS 10Y AVG
+58.24%
CURRENT VS 15Y AVG
+44.05%
CURRENT VS 20Y AVG
-0.13%
SECTOR MEDIAN · HEALTHCARE
-29.10%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
+37.53%
vs the sector median at left
Aurora Cannabis Inc.
Market Cap
$276.57M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
Market Cap
$274.50M
Return on Assets (ROA)
-48.44%
TTM Avg
-42.51%
3Y Avg
-39.18%
5Y Avg
-34.60%
Market Cap
$272.91M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
Market Cap
$282.07M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$284.12M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$266.10M
Return on Assets (ROA)
-13.63%
TTM Avg
-10.56%
3Y Avg
-3.47%
5Y Avg
-3.69%
Market Cap
$289.31M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$263.68M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$262.58M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aurora Cannabis Inc. (ACB) | $276.57M | -18.18% | -10.00% | -29.10% | -54.94% |
| Fate Therapeutics, Inc. (FATE)vs › | $274.50M | -48.44% | -42.51% | -39.18% | -34.60% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | -128.66% | -214.31% | -145.75% | -133.94% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.07M | -26.24% | -12.09% | -27.60% | -33.24% |
| Abeona Therapeutics Inc. (ABEO)vs › | $284.12M | -35.03% | -13.04% | -43.14% | -55.84% |
| OraSure Technologies, Inc. (OSUR)vs › | $266.10M | -13.63% | -10.56% | -3.47% | -3.69% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $289.31M | -104.42% | -76.93% | -55.08% | -54.19% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.68M | -134.38% | -47.50% | -42.91% | -40.55% |
| AC Immune S.A. (ACIU)vs › | $262.58M | -29.15% | -33.84% | -33.85% | -31.54% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.48M | -35.96% | -58.88% | -82.10% | -113.46% |
ROA
-18.2%
ROE
-21.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -20.20% |
| 2025-03-31 | 0.19% |
| 2024-03-31 | -8.25% |
| 2023-03-31 | -88.15% |
| 2022-06-30 | -187.74% |
| 2021-06-30 | -25.49% |
| 2020-06-30 | -112.54% |
| 2019-06-30 | -5.21% |
| 2018-06-30 | 3.79% |
| 2017-06-30 | -4.00% |
| 2016-06-30 | -31.24% |
| 2015-06-30 | -69.93% |
| 2014-06-30 | -21.09% |
| 2013-06-30 | -54.83% |
| 2012-06-30 | -27.27% |
| 2011-06-30 | -23.21% |
| 2010-06-30 | -2.54% |
| 2009-06-30 | -8.97% |
| 2008-06-30 | -10.49% |
| 2007-06-30 | 0.07% |
